IPO Review: Windlas Biotech
Moneylife Digital Team 04 August 2021
Windlas Biotech Ltd (WBL) is amongst the top-5 players in the domestic contract development and manufacturing organisation (CDMO) of pharmaceutical formulations in India, in terms of revenues. WBL provides CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics. However, the industry is highly...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
Already a subscriber ? Log in
Free Helpline
Legal Credit